DIVISION OF RHEUMATIC DISEASES
Clinical Research
We focus on phase II, III, and IV research. Our therapeutic
specialties include the following:
- Rheumatoid arthritis
- Osteoarthritis
- Systemic lupus erythematosus
- Sjögren's syndrome
- Osteoporosis
- Scleroderma
We have worked with the following sponsors:
- Purdue Frederick
- Syntex
- 3M
- Pfizer
- Sandoz
- La Jolla Pharmaceuticals
- Berlex
- Genelabs
- MGI Pharma
- Connectics
- Bayer
- Pfizer
Our Division Focuses on An Essential Multidisciplinary Approach
To Fibromyalgia, Polymyositis/Dermatomyositis,Tendonitis
and Bursitis
Dr. Abeles is involved in Fibromyalgia research; he is an expert in
inflammatory diseases that involve soft tissue and muscles including:
Lyme Arthritis, Rheumatoid Arthritis and Osteoarthritis
Dr. Rothfield
studies patients with scleroderma and Raynaud's disease
- Clinical Trials
- Read about the ongoing Clinical Trials related to Scleroderma and Raynaud's.
-
- Finished Trials
- A Multicenter Double-Blinded Study of
Relaxin was completed in 1997 and published in the
June 2000 issue of Annals of Internal Medicine: (Recombinant human
relaxin in the treatment of scleroderma. A randomized, double-blind,
placebo-controlled trial. Ann Intern Med.
2000 Jun 6:132(11):871-9.)
-
- Treatment of
severe Raynaud's
-
- recombinant Tissue Plasminogen Activator (rTPA)
-
Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and
Sjögren's Syndrome
- These are areas of interest of Dr. Parke
and Dr. Rothfield especially in the field of
lupus and pregnancy.
-
- Dr. Rothfield is an active investigator involved in Clinical Trials to evaluate the efficacy and safety
of novel treatments for Lupus.
-
- Dr. Parke evaluated new therapies in patients
with Sjögren's Syndrome.
Back to Home Page: Division of Rheumatic Diseases
__________________________________________
This site was created by Dolores Vázquez-Abad, MD, and is
maintained by Naomi F. Rothfield, MD, © Copyright
1997. All rights
reserved. If you experience any broken links or other
difficulties with this site, please email
us.